Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer: Progress and Challenges. (July 2020)

• Record Type: Journal Article
• Authors: Warrick, Joshua I.; Knowles, Margaret A.; Yves, Allory; van der Kwast, Theo; Grignon, David J.; Kristiansen, Glen; Egevad, Lars; Hartmann, Arndt; Cheng, Liang
• Is Part Of: American journal of surgical pathology. Volume 44:Number 7(2020)
• Publication Date: 2020-07
• Subjects: bladder cancer -- molecular subtypes -- immune-oncology -- FGFR3 mutation -- TERT promoter -- PD-L1 immunohistochemistry; Pathology, Surgical -- Periodicals; 617.0705
• DOI: 10.1097/PAS.0000000000001453
• Languages: English
• ISSNs: 0147-5185

Abstract

Abstract : During the 2019 International Society of Urological Pathology Consultation Conference on Molecular Pathology of Urogenital Cancer, the Working Group on Bladder Cancer presented the current status and made recommendations on the diagnostic use of molecular pathology, incorporating a premeeting survey. Bladder cancers are biologically diverse and can be separated into "molecular subtypes, " based on expression profiling. These subtypes associate with clinical behavior, histology, and molecular alterations, though their clinical utility has not been demonstrated at present and use in bladder cancer is not recommended. Mutations in the TERT promoter are present in the majority of bladder cancers, including the noninvasive stage of tumor evolution, but not in reactive conditions. Mutational analysis of the TERT promoter thus distinguishes histologically deceptive cancers from their benign mimics in some cases. A minority of pathologists employ this test. FGFR3 mutations are common in bladder cancer, and metastatic urothelial carcinoma (UC) with such mutations frequently responds to erdafitinib, an FGFR inhibitor. Testing for FGFR3 alterations is required before using this drug. Metastatic UC responds to immune-oncology (IO) agents in 20% of cases. These are approved as first and second-line treatments in metastatic UC. Several biological parameters associate with response to IO agents, including tumor mutational burden, molecular subtype, and infiltration by programmed death-ligand 1–positive lymphocytes, detected by immunohistochemistry. Programmed death-ligand 1 immunohistochemistry is mandatory before administering IO agents in the first-line setting. In conclusion, much has been learned about the biology of bladder cancer, and this understanding has improved the care of patients with the disease.